Central nervous system progression in advanced non–small cell lung cancer patients with EGFR mutations in response to first-line treatment with two EGFR-TKIs, gefitinib and erlotinib: a comparative study

BACKGROUND: Central nervous system (CNS) brain metastasis of advanced non-small cell lung cancer (NSCLC) patients confers a worse quality of life and prognosis. The efficacy comparison of two first-generation epidermal growth factor receptor (EGFR) inhibitors erlotinib or gefitinib as first-line tre...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Meng-Xia, He, Hao, Ruan, Zhi-Hua, Zhu, Yu-Xi, Li, Rong-Qing, He, Xiao, Lan, Bao-Hua, Zhang, Zhi-Min, Liu, Guo-Dong, Xiao, Hua-Liang, Wu, Yan, Zhu, Bo, Wang, Ge, Yang, Zhen-Zhou
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5379522/
https://www.ncbi.nlm.nih.gov/pubmed/28376735
http://dx.doi.org/10.1186/s12885-017-3165-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5379522/
https://www.ncbi.nlm.nih.gov/pubmed/28376735
http://dx.doi.org/10.1186/s12885-017-3165-0

Ejemplares similares